Unicycive Therapeutics Engages Investors at Virtual Conference
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), based in Los Altos, California, is gearing up to take part in a significant investor conference focused on therapies for kidney diseases. The company's Chief Executive Officer, Dr. Shalabh Gupta, is set to engage in a fireside chat during the Lytham Partners Fall 2024 Investor Conference.
What to Expect from the Investor Conference
This virtual event will take place on October 1, 2024, at 11:00 a.m. ET, serving as a valuable platform for investors and stakeholders eager to learn more about Unicycive's advancements in biotechnology, particularly their innovative approaches to treating chronic kidney disease. Dr. Gupta will provide insights into the company's pioneering strategies and dedication to developing crucial therapies for patients in need.
About Unicycive's Innovative Treatments
Unicycive is particularly notable for its groundbreaking work in treating kidney disease. Their lead therapeutic candidate, oxylanthanum carbonate (OLC), is a new investigational phosphate-binding agent designed to manage hyperphosphatemia—an issue commonly faced by patients with chronic kidney disease undergoing dialysis.
Considerable Advancements with UNI-494
Alongside OLC, Unicycive is pushing forward with UNI-494, a new chemical compound currently being tested for treating conditions associated with acute kidney injury. These initiatives underscore Unicycive's steadfast commitment to research and innovation in the biotechnology field, specifically for patients grappling with kidney-related challenges.
Accessibility of Conference Resources
To enhance accessibility, a live webcast of the fireside chat will be available on the Unicycive website under the Investors section. This feature allows both live participants and those who can’t join at that time to experience the discussion, with an archive accessible for three months after the event. Such offerings reflect Unicycive's commitment to transparent communication with its investor base.
A Look at Company Resources
For more detailed information about Unicycive Therapeutics and its product candidates, stakeholders are encouraged to visit the company’s official website. Additionally, prospective investors and interested individuals can follow Unicycive on various social media platforms, including LinkedIn and YouTube, to keep up with the latest updates and developments.
Contact Information for Investors
Investors looking for more details can reach the company via email at ir@unicycive.com or by phone at (650) 543-5470. This direct communication line reinforces Unicycive's dedication to fostering strong investor relations and providing solid customer support.
Frequently Asked Questions
What is Unicycive Therapeutics known for?
Unicycive Therapeutics is known for developing innovative therapies specifically aimed at treating kidney diseases.
Who will represent Unicycive at the upcoming conference?
Dr. Shalabh Gupta, the Chief Executive Officer, will represent Unicycive at the investor conference.
When will the conference take place?
The virtual Lytham Partners Fall 2024 Investor Conference is set for October 1, 2024.
How can investors access the fireside chat?
Investors can access the live and archived webcast through the Investors section of the Unicycive website.
What are the key products in Unicycive's pipeline?
Unicycive's key products include oxylanthanum carbonate (OLC) and UNI-494, which target various conditions related to kidney disease.